{
    "clinical_study": {
        "@rank": "4874", 
        "acronym": "Brilliance", 
        "arm_group": [
            {
                "arm_group_label": "Group I", 
                "arm_group_type": "Experimental", 
                "description": "0.5 mg ranibizumab driven by visual acuity stability criteria"
            }, 
            {
                "arm_group_label": "Group II", 
                "arm_group_type": "Experimental", 
                "description": "0.5 mg ranibizumab driven by disease activity criteria"
            }, 
            {
                "arm_group_label": "Group III", 
                "arm_group_type": "Active Comparator", 
                "description": "verteporfin PDT"
            }
        ], 
        "brief_summary": {
            "textblock": "This study is designed to evaluate the efficacy and safety of two different dosing regimens\n      of 0.5 mg ranibizumab given as intravitreal injection in comparison to verteporfin PDT in\n      patients with visual impairment due to choroidal neovascularization secondary to pathologic\n      myopia (PM)"
        }, 
        "brief_title": "Efficacy and Safety of Ranibizumab 0.5 vs Veteporfin PDT in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia", 
        "completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia", 
        "condition_browse": {
            "mesh_term": [
                "Myopia", 
                "Neovascularization, Pathologic", 
                "Vision, Low", 
                "Vision Disorders", 
                "Choroidal Neovascularization"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a phase III, multi-center, randomized, double-masked, active-controlled study\n      comparing 0.5 mg ranibizumab vs. vPDT therapy. The study includes 15 scheduled visits over\n      12 months, and there will be two additional visits (2a, 3a) for subset of patients in whom\n      PK analysis will be performed.\n\n      There will be 3 periods in this study: Screening period-from Day -14 to Baseline; Treatment\n      period-from Baseline to Month 11; Follow-up period-from Month 11 to Month 12 Patients will\n      enter the 11 months Treatment period at Visit 2 (Day 1) if eligibility criteria are met and\n      will be randomized in three treatment groups Group I ranibizumab 0.5 mg driven by VA\n      stability criteria or Group II ranibizumab 0.5 mg driven by disease activity criteria or\n      Group III vPDT (randomization ratio of 2:2:1) and will receive first treatment of either a\n      ranibizumab injection and sham vPDT or sham injection and active vPDT and will return to the\n      clinical center within 7 days to undergo safety assessments as well as assessments of the\n      effect of treatment by the evaluating investigator. The following visits will be performed\n      at one month intervals starting at Visit 4 and continuing through Visit 14.At all monthly\n      visits (at/from Month 2 for group I, at/from Month 1 for group II and at/from Month 3 for\n      group III) the decision for treatment will be made by the evaluating investigator based on\n      the VA stability criteria and on the disease activity criteria. At Month 3 (visit 6) and at\n      all following monthly visits for all three groups one of the three options can recommended\n      by evaluating investigator: a) ranibizumab 0.5 mg, b) ranibizumab 0.5 mg + vPDT; c) vPDT.\n      The treating investigator will then perform treatment based on randomization and masking\n      requirements.\n\n      At each monthly visit, patients will have a safety evaluation by the evaluating investigator\n      prior to study treatment, consisting of visual acuity measurements, ophthalmic examinations\n      and evaluation of adverse events and vital signs. Routine hematology, chemistry, and\n      urinalysis profiles will be obtained at Visit 6, 9 and 12 (Month 3, 6 and 9). At Month 12\n      several procedures and assessments will be performed which are required at study completion\n      visit."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Visual impairment due to CNV secondary to PM.\n\n          -  Best corrected visual acuity in the study eye > 24 and < 78 ETDRS letters.\n\n          -  High myopia (> -6D),\n\n          -  anterio-posterior elongation > 26 mm; posterior changes compatible with the\n             pathologic myopia.\n\n          -  Either CNV locations in the study eye: subfoveal, juxtafoveal, extrafoveal.\n\n        Exclusion Criteria:\n\n          -  Some preexisting eye disorders or systemic diseases;-Blood pressure > 150/90 mmHg\n\n          -  Prior focal/grid laser to the macular area -History of treatment with any anti-VEGF\n             or verteporfin PDT in the study eye\n\n          -  Intravitreal treatment with corticosteroids or intraocular surgery within last 3\n             months in the study eye\n\n          -  Other protocol-defined inclusion/exclusion criteria may apply"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "475", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 12, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01922102", 
            "org_study_id": "CRFB002F2302"
        }, 
        "intervention": [
            {
                "arm_group_label": "Group I", 
                "description": "0.5 mg ranibizumab (intravitreal injections)", 
                "intervention_name": "Ranibizumab 0.5mg", 
                "intervention_type": "Drug", 
                "other_name": "Lucentis"
            }, 
            {
                "arm_group_label": "Group II", 
                "description": "0.5 mg ranibizumab (intravitreal injections)", 
                "intervention_name": "Rranibizumab 0.5 mg", 
                "intervention_type": "Drug", 
                "other_name": "Lucentis"
            }, 
            {
                "arm_group_label": "Group III", 
                "description": "Verteporfin for intravenous injection delivered by intravenous infusion followed by the light application", 
                "intervention_name": "Verteporfin PDT", 
                "intervention_type": "Drug", 
                "other_name": "Visudyne"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Verteporfin"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Pathologic myopia (PM), choroidal neovascularization (CNV), ranibizumab, verteporfin PDT, Brilliance", 
        "lastchanged_date": "January 17, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China", 
                        "state": "Beijing", 
                        "zip": "100730"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China", 
                        "state": "Beijing", 
                        "zip": "100083"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chongqing", 
                        "country": "China", 
                        "state": "Chongqing", 
                        "zip": "400042"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Harbin", 
                        "country": "China", 
                        "state": "Heilongjiang", 
                        "zip": "150086"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Wuhan", 
                        "country": "China", 
                        "state": "Hubei", 
                        "zip": "430070"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Changsha", 
                        "country": "China", 
                        "state": "Hunan", 
                        "zip": "410008"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Changsha", 
                        "country": "China", 
                        "state": "Hunan", 
                        "zip": "410011"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nanjing", 
                        "country": "China", 
                        "state": "Jiangsu", 
                        "zip": "210006"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nanjing", 
                        "country": "China", 
                        "state": "Jiangsu", 
                        "zip": "210029"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Wu Xi", 
                        "country": "China", 
                        "state": "Jiangsu", 
                        "zip": "214023"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nanchang", 
                        "country": "China", 
                        "state": "Jiangxi", 
                        "zip": "330006"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Qingdao", 
                        "country": "China", 
                        "state": "Shandong", 
                        "zip": "266011"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Xi'an", 
                        "country": "China", 
                        "state": "Shanxi", 
                        "zip": "710032"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chengdu", 
                        "country": "China", 
                        "state": "Sichuan", 
                        "zip": "610041"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tianjin", 
                        "country": "China", 
                        "state": "Tianjin", 
                        "zip": "300070"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tianjin", 
                        "country": "China", 
                        "state": "Tianjin", 
                        "zip": "300020"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hangzhou", 
                        "country": "China", 
                        "state": "Zhejiang", 
                        "zip": "310009"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Wenzhou", 
                        "country": "China", 
                        "state": "Zhejiang", 
                        "zip": "325027"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China", 
                        "zip": "100176"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China", 
                        "zip": "100034"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chongqing", 
                        "country": "China", 
                        "zip": "400038"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shanghai", 
                        "country": "China"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shanghai", 
                        "country": "China", 
                        "zip": "200092"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shanghai", 
                        "country": "China", 
                        "zip": "200080"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shenyang", 
                        "country": "China", 
                        "zip": "110001"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bangalore", 
                        "country": "India", 
                        "state": "Karnataka", 
                        "zip": "560 010"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bangalore", 
                        "country": "India", 
                        "state": "Karnataka", 
                        "zip": "560054"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Mumbai", 
                        "country": "India", 
                        "state": "Maharashtra", 
                        "zip": "400031"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chennai", 
                        "country": "India", 
                        "state": "Tamil Nadu", 
                        "zip": "600006"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madurai", 
                        "country": "India", 
                        "state": "Tamil Nadu", 
                        "zip": "625020"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Salem", 
                        "country": "India", 
                        "state": "Tamil Nadu", 
                        "zip": "636 004"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hyderabad", 
                        "country": "India", 
                        "zip": "500034"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New Delhi", 
                        "country": "India", 
                        "zip": "110 029"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pusan", 
                        "country": "Korea, Republic of", 
                        "zip": "614-735"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "zip": "135-720"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "zip": "136 705"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Manila", 
                        "country": "Philippines", 
                        "state": "Metro Manila", 
                        "zip": "1008"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Manila", 
                        "country": "Philippines", 
                        "zip": "1000"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bangkok", 
                        "country": "Thailand", 
                        "zip": "10700"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chiang Mai", 
                        "country": "Thailand", 
                        "zip": "50200"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Khon Kaen", 
                        "country": "Thailand", 
                        "zip": "40002"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nakornphathom", 
                        "country": "Thailand", 
                        "zip": "73210"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "China", 
                "India", 
                "Korea, Republic of", 
                "Philippines", 
                "Thailand"
            ]
        }, 
        "number_of_arms": "3", 
        "official_title": "A 12-month, Phase III, Randomized, Double-masked, Multicenter, Active-controlled Study to Evaluate the Efficacy and Safety of Two Individualized Regimens of 0.5mg Ranibizumab vs. Verteporfin PDT in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia", 
        "overall_contact": {
            "last_name": "Novartis Pharmaceuticals", 
            "phone": "+41613241111"
        }, 
        "overall_contact_backup": {
            "last_name": "Novartis Pharmaceuticals"
        }, 
        "overall_official": {
            "affiliation": "Novartis Pharmaceuticals", 
            "last_name": "Novartis Pharmaceuticals", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Superior efficacy of 0.5 mg ranibizumab administered based on visual acuity stability criteria and/or disease activity re-treatment criteria compared to vPDT", 
            "measure": "change from baseline BCVA to the average level of BCVA (letters) over all monthly post-baseline assessments: BCVA change; by measuring BCVA score at 4 meters distance using Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity charts", 
            "safety_issue": "No", 
            "time_frame": "Month 1 to Month 3"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01922102"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "demonstrate non-inferiority of 0.5 mg ranibizumab intravitreal injections driven by disease activity re-treatment criteria versus 0.5 mg ranibizumab intravitreal injections driven by visual acuity stability criteria as assessed by the change from baseline BCVA to the average level of BCVA over all monthly assessments from Month 1 to Month 6.", 
                "measure": "average level of BCVA (letters); BCVA change; by measuring BCVA score at 4 meters distance using Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity charts", 
                "safety_issue": "No", 
                "time_frame": "Month 1 to Month 6"
            }, 
            {
                "description": "To compare the efficacy of the ranibizumab treatment groups as assessed by the change from baseline BCVA to the average level of BCVA over all monthly assessments from Month 1 to Month 12 and based on the time course of BCVA changes from baseline", 
                "measure": "average level of BCVA (letters); BCVA change; by measuring BCVA score at 4 meters distance using Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity charts", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "To compare  BCVA improvement  \u226510 and \u226515 letters or BCVA reaching 84 letters, and BCVA loss \u226510 and  \u226515 letters for each month between treatment groups", 
                "measure": "Improvement in BCVA; BCVA score measured at 4 meters distance using Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity charts", 
                "safety_issue": "No", 
                "time_frame": "12 Months"
            }, 
            {
                "description": "To evaluate the time course of CRT/CSFT changes from baseline in the treatment groups", 
                "measure": "Change in retinal thickness measured on OCT image by Reading center", 
                "safety_issue": "No", 
                "time_frame": "12 Months"
            }, 
            {
                "description": "To compare presence of active leakage over time up to Month 12 in the treatment groups", 
                "measure": "CNV leakage presence measured on Fluorescein angiography image by Reading center", 
                "safety_issue": "No", 
                "time_frame": "12 Months"
            }, 
            {
                "description": "To assess the impact on patient functioning and quality of life supported by ranibizumab 0.5 versus vPDT as assessed by the NEI-VFQ-25", 
                "measure": "Quality of Life", 
                "safety_issue": "No", 
                "time_frame": "12 Months"
            }, 
            {
                "description": "To assess treatment pattern with ranibizumab", 
                "measure": "Number of injections and period (time) between injections", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }, 
            {
                "description": "To assess the safety and tolerability of 0.5 mg ranibizumab and vPDT", 
                "measure": "Occurrence and incidence of the AEs", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }
        ], 
        "source": "Novartis", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novartis Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}